Subscribe for email alerts
Donate to Science & Enterprise
|
By Alan, on August 22nd, 2023%
A company creating a digital process to monitor farm insect pests is receiving funds to expand its technology for tracking and counting mosquitoes as a general public health threat. . . . → Read More: Small Biz Award Funds A.I. Mosquito Monitoring System
By Alan, on August 21st, 2023%
A company developing a drug delivery process with treatments activated by ultrasound received an option to license a key technology from its founders’ university labs. . . . → Read More: Company Gains Ultrasound-Linked Drug Capsule Technology
By Alan, on August 18th, 2023%
A discoverer of neuroscience therapies and a genomics data science company are developing machine learning models to predict clinical trial outcomes for ADHD drugs. . . . → Read More: Biotech, A.I. Companies Model Animal Studies/Clinical Trials
By Alan, on August 16th, 2023%
A clinical trial has begun testing an experimental treatment for burns using off-the-shelf therapeutic particles derived from human bone marrow stem cells. . . . → Read More: Trial Underway Testing Stem Cell Particles for Burns
By Alan, on August 15th, 2023%
Data scientists and cancer specialists demonstrate a data encryption technique that makes possible real-world cancer data sharing while preserving individual privacy. . . . → Read More: Advanced Encryption Shown to Enable Cancer Data Sharing
By Alan, on August 14th, 2023%
A developer of electronic health data tools and a university’s neuroscience labs are collaborating on tests of Parkinson’s disease drugs using digital measures of patient functioning. . . . → Read More: Industry, Univ. Labs Partner on Parkinson’s Digital Biomarkers
By Alan, on August 11th, 2023%
Findings from two clinical trials show a digital health mobile app helps improve outcomes and manage the conditions for people with depression and asthma. . . . → Read More: Health App Shown to Improve Asthma, Depression Outcomes
By Alan, on August 9th, 2023%
Regeneron Pharmaceuticals, a maker of synthetic biologic treatments, is acquiring Decibel Therapeutics, developer of gene therapies to treat hearing loss and balance disorders. . . . → Read More: Regeneron Acquires Hearing Loss Biotech in $213M Deal
By Alan, on August 8th, 2023%
A women’s health biotechnology company is partnering with a Brazilian drug maker to evaluate a precision target and treatment for ovarian health disorders. . . . → Read More: Companies to Assess Ovarian Health Biotech Drug
By Alan, on August 7th, 2023%
Initial findings from a large clinical trial testing a vaccine against the chikungunya virus show the vaccine generates protective antibodies in the vast majority of recipients. . . . → Read More: Trial Shows Vaccine Induces Chikungunya Immune Response
|
Welcome to Science & Enterprise Science and Enterprise is an online news service begun in 2010, created for researchers and business people interested in taking scientific knowledge to the marketplace.
On the site’s posts published six days a week, you find research discoveries destined to become new products and services, as well as news about finance, intellectual property, regulations, and employment.
|